Equipoise can produce androgenic side effects such as acne, accelerated hair loss in those predisposed to male pattern baldness and body hair growth. However, the overall androgenicity of this steroid is greatly reduced due to the structural nature that creates EQ in its double bond at the carbon one and two position. Such side effects of Equipoise are still possible, but they will be strongly linked to genetic predisposition, but most will find the threshold is fairly high.
When combating the possible androgenic side effects of Equipoise, it’s important to note they are brought on by the steroid being metabolized by the 5-alpha reductase enzyme. This metabolism will reduce Boldenone to an extremely potent androgen in dihydroboldenone, far more potent than dihydrotestosterone (DHT); however, the total dihydroboldenone activity has proven to be extremely low in human beings. You will further find the androgenic nature of Boldenone will not be significantly affected by 5-alpha reductase inhibitors like Finasteride that are often used to combat the reduction to DHT.
Due to the androgenic nature of Equipoise, women may potentially experience virilization symptoms. Virilization symptoms may include body hair growth, a deepening of the vocal chords and clitoral enlargement. However, the low androgenicity will make this steroid possible to use for some women without such symptoms. At the same time, the extremely slow acting nature of the compound can make it difficult to control regarding blood levels, and alternative steroids may be preferred. Without question, individual sensitivity will dictate a lot. If Equipoise is used and virilization symptoms begin to show, use should be discontinued immediately at their onset and they will fade away. If symptoms begin to show and are ignored, the symptoms may become irreversible.
Blinding : the process of preventing one or more of patients, clinicians, investigators, and data analysts from knowing whether individual patients are receiving the investigational intervention(s) or the control (or standard) intervention(s) in a clinical trial. (Also known as masking.) Blinding is intended to eliminate the possibility that knowledge of which intervention is being received will affect patient outcomes, investigator behaviors that may affect outcomes, or assessment of outcomes. Blinding is not always practical (. when comparing surgery to drug treatment), but it should be used whenever it is possible and compatible with optimal patient care. The terms “single-blinded,” “double-blinded,” and “triple-blinded” refer to which parties are blinded, ., one or more of patients, investigators, and data analysts; however, these terms are used inconsistently and the specific parties who are blinded in a trial should be identified.